A different role for FDG PET/CT in axillary lymph node staging in breast cancer

2009 ◽  
Vol 36 (11) ◽  
pp. 1896-1897 ◽  
Author(s):  
Tjeerd S. Aukema ◽  
Marieke E. Straver ◽  
Renato A. Valdés Olmos ◽  
Wouter V. Vogel
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Fdg Pet ◽  
Axillary Lymph Node ◽  
Lymph Node Staging ◽  
Axillary Lymph ◽  
Pet Ct ◽  
Fdg Pet Ct

Reply to the Letter “A different role of FDG PET/CT for axillary lymph node staging in breast cancer”

2009 ◽  
Vol 36 (11) ◽  
pp. 1898-1899
Author(s):  
Till A. Heusner ◽  
Sherko Kuemmel ◽  
Gerald Antoch ◽  
Alexander R. Stahl
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Fdg Pet ◽  
Axillary Lymph Node ◽  
Lymph Node Staging ◽  
Axillary Lymph ◽  
Pet Ct ◽  
Fdg Pet Ct

Diagnostic and prognostic value of 18F-FDG PET/CT for axillary lymph node staging in patients with breast cancer

2015 ◽  
Vol 34 (3) ◽  
pp. 220-228 ◽  
Author(s):  
Kazuhiro Kitajima ◽  
Kazuhito Fukushima ◽  
Yasuo Miyoshi ◽  
Takayuki Katsuura ◽  
Yoko Igarashi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Axillary Lymph Node ◽  
Prognostic Value ◽  
Lymph Node Staging ◽  
Axillary Lymph ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Diagnostic And Prognostic Value

Value of F-18 FDG PET/CT in detection and prognostication of isolated extra-axillary lymph node recurrences in postoperative breast cancer

2014 ◽  
Vol 24 (1) ◽  
pp. 1173-1184
Author(s):  
Jin Kyoung Oh ◽  
Yong An Chung ◽  
Yeon Sil Kim ◽  
Hae Myung Jeon ◽  
Sung Hoon Kim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Fdg Pet ◽  
Axillary Lymph Node ◽  
Axillary Lymph ◽  
Pet Ct ◽  
Fdg Pet Ct

Early and delayed prediction of axillary lymph node neoadjuvant response by 18F-FDG PET/CT in patients with locally advanced breast cancer

2014 ◽  
Vol 41 (7) ◽  
pp. 1309-1318 ◽  
Author(s):  
Ana María García Vicente ◽  
Ángel Soriano Castrejón ◽  
Alberto León Martín ◽  
Fernanda Relea Calatayud ◽  
María del Mar Muñoz Sánchez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Fdg Pet ◽  
Axillary Lymph Node ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Axillary Lymph ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II–III breast cancer

2010 ◽  
Vol 46 (18) ◽  
pp. 3205-3210 ◽  
Author(s):  
Tjeerd S. Aukema ◽  
Marieke E. Straver ◽  
Marie-Jeanne T.F.D. Vrancken Peeters ◽  
Nicola S. Russell ◽  
Kenneth G.A. Gilhuijs ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Fdg Pet ◽  
Axillary Lymph Node ◽  
Lymph Node Involvement ◽  
Axillary Lymph ◽  
Pet Ct ◽  
Node Involvement ◽  
Fdg Pet Ct ◽  
Axillary Lymph Node Involvement

scholarly journals The role of FDG-PET-CT in the evaluation of primary systemic therapy in breast cancer: links between metabolic and pathological remission

2012 ◽  
Vol 153 (49) ◽  
pp. 1958-1964 ◽  
Author(s):  
Tímea Tőkés ◽  
Krisztián Somlai ◽  
Borbála Székely ◽  
Janina Kulka ◽  
Gyöngyvér Szentmártoni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Fdg Pet ◽  
Axillary Lymph Node ◽  
Primary Tumour ◽  
Axillary Lymph ◽  
Proliferation Marker ◽  
Ki 67 ◽  
Pet Ct ◽  
Fdg Pet Ct

Introduction: FDG-PET-CT is highly sensitive in detection of viable tumour tissue, giving an importance for that in oncological diagnostics. Aim: The authors analysed retrospectively the relationship between metabolic response and changes in Ki-67, a proliferation marker. Methods: Staging FDG-PET-CT scans (before and after therapy) SUVs (Standardized Uptake Value), and morphological changes in the primary tumour and axillary lymph node region were evaluated in 30 patients with breast cancer. Calculated ΔSUV were compared with Ki-67 proliferation marker (measured in biopsies and surgical specimens). Results: The decrease of SUV and size were significant in the primary tumour and the axillary lymph node region. Decrease of Ki-67 was significant. Significant correlation was found between Ki-67 and SUV before therapy, initial Ki-67 and ΔSUV, and ΔKi-67 and ΔSUV. Conclusions: The metabolic changes were more sensitive in the measurement of the therapeutic response than morphological remission, and they correlated well with the pathological response, in not standardized clinical conditions even. Orv. Hetil., 2012, 153, 1958–1964.

Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients

2009 ◽  
Vol 36 (10) ◽  
pp. 1543-1550 ◽  
Author(s):  
Till A. Heusner ◽  
Sherko Kuemmel ◽  
Steffen Hahn ◽  
Angela Koeninger ◽  
Friedrich Otterbach ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Axillary Lymph Node ◽  
Diagnostic Value ◽  
Lymph Node Staging ◽  
Axillary Lymph ◽  
Breast Cancer Patients ◽  
Pet Ct ◽  
Fdg Pet Ct

Diagnostic performance of 18F-FDG PET/CT, ultrasonography and MRI

2014 ◽  
Vol 53 (03) ◽  
pp. 89-94 ◽  
Author(s):  
D. H. Lee ◽  
J.-K Yoon ◽  
S. J. Lee ◽  
T. H. Kim ◽  
D. K. Kang ◽  
...  
Keyword(s):  
Lymph Node ◽  
Fdg Pet ◽  
Axillary Lymph Node ◽  
Diagnostic Performance ◽  
Axillary Lymph ◽  
Diagnostic Ability ◽  
Node Metastasis ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

SummaryThe aim of this study was to evaluate the diagnostic abilities of 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) compared with those of ultrasonography and magnetic resonance imaging (MRI) for axillary lymph node staging in breast cancer patients. Patients, methods: Pre- operative 18F-FDG PET/non-contrast CT, ultrasonography and MRI were performed in 215 women with breast cancer. Axillary lymph node dissection was performed in all patients and the diagnostic performance of each modality was evaluated using histopathologic assessments as the reference standard. ROC curves were compared to evaluate the diagnostic ability of several imaging modalities (i. e., ultrasonography, MRI and 18F-FDG PET/CT). Results: In total, 132 patients (61.4%) had axillary lymph node metastasis. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for the detection of axillary lymph node metastasis were 72.3%, 77.3%, 66.7%, 81.6%, 75.3% for ultrasonography, 67.5%, 78.0%, 65.9%, 79.2%, 74.0% for MRI, and 62.7%, 88.6%, 77.6%, 79.1%, 78.6% for 18F-FDG PET/CT, respectively. There was no significant difference in diagnostic ability among the imaging modalities (i.e., ultrasonography, MRI and 18F-FDG PET/CT). The diagnostic ability of 18F-FDG PET/CT was significantly improved by combination with MRI (p = 0.0002) or ultrasonography (p < 0.0001). The combination of 18F-FDG PET/CT with ultrasonography had a similar diagnostic ability to that of all three modalities combined (18F-FDG PET/CT+ultraso- nography+MRI, p = 0.05). Conclusion: The diagnostic performance of 18F-FDG PET/CT for detection of axillary node metastasis was not significantly different from that of ultrasonography or MRI in breast cancer patients. Combining 18F-FDG PET/CT with ultrasonography or MRI could improve the diagnostic performance compared to 18F-FDG PET/CT alone.

Sign in / Sign up

Export Citation Format

Share Document